I have been a Postdoctoral Research Fellow at the Massachusetts Eye and Ear and Harvard Medical School since 2022, working with Prof. Dr. Michael S. Gilmore. Since 2023, I have also been affiliated with the Infectious Disease and Microbiome Program at the Broad Institute of MIT and Harvard, where I collaborate with the Bacterial Genomics Group, led by Dr. Ashlee M. Earl and Dr. Abigail L. Manson. My work integrates comparative genomics, molecular microbiology, and microbial ecology to investigate the evolutionary dynamics, adaptation, and dissemination of bacterial pathogens across clinical, environmental, animal, and human-associated ecosystems, with a particular emphasis on multidrug-resistant Gram-positive bacteria, especially enterococci.
Currently, I lead studies focused on the discovery, characterization, and engineering of Efagins, novel phage-related antibacterial nanomachines, as precision antimicrobial agents against multidrug-resistant bacteria. Through interdisciplinary approaches integrating genomics, molecular microbiology, and structural biology, I aim to contribute to advancing the development of next-generation targeted therapies as alternatives to conventional antibiotics.
I have been a Postdoctoral Research Fellow at the Massachusetts Eye and Ear and Harvard Medical School since 2022, working with Prof. Dr. Michael S. Gilmore. Since 2023, I have also been affiliated with the Infectious Disease and Microbiome Program at the Broad Institute of MIT and Harvard, where I collaborate with the Bacterial Genomics Group, led by Dr. Ashlee M. Earl and Dr. Abigail L. Manson. My work integrates comparative genomics, molecular microbiology, and microbial ecology to investigate the evolutionary dynamics, adaptation, and dissemination of bacterial pathogens across clinical, environmental, animal, and human-associated ecosystems, with a particular emphasis on multidrug-resistant Gram-positive bacteria, especially enterococci.
Currently, I lead studies focused on the discovery, characterization, and engineering of Efagins, novel phage-related antibacterial nanomachines, as precision antimicrobial agents against multidrug-resistant bacteria. Through interdisciplinary approaches integrating genomics, molecular microbiology, and structural biology, I aim to contribute to advancing the development of next-generation targeted therapies as alternatives to conventional antibiotics.